miRagen Therapeutics, Inc, a biopharmaceutical company working to develop microRNA-based therapeutic agents for a range of diseases, recently announced the initiation of a Phase I clinical study assessing MRG-201, the company’s lead anti-fibrotic candidate, in healthy patients. The study has the potential to be extended to patients with cutaneous scleroderma. MRG-201…
News
Genkyotex, a company focused on developing therapies for hard-to-treat chronic diseases, recently announced that the company’s lead product candidate GKT137831, a drug developed for systemic sclerosis treatment, has been granted Orphan Drug designation by both the U.S. Food and Drug Administration (FDA) and its counterpart in Europe, the European…
The nonprofit association phaware is dedicated to raising global awareness of a common complication in patients with scleroderma, the chronic lung disease known as pulmonary hypertension (PH). phaware connects with innovative technologies and industry leaders to find new paths to a PH cure and, from one of these collaborations, comes a new mobile app allowing users…
New data recently presented at the 2015 American College of Rheumatology Annual Meeting in San Francisco showed that mycophenolate mofitil is as efficient as cyclophosphamide for the treatment of interstitial lung disease in individuals with scleroderma. Scleroderma, or systemic sclerosis, is a chronic systemic autoimmune disease characterized by a…
Researchers at St. Elizabeth’s Medical Center in Stow, Massachusetts, recently reported a clinical case of pulmonary lymphoma in a patient diagnosed with scleroderma. The data was presented at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, under the title “…
What is it like living with scleroderma? This video takes a look at some of the struggles that patients face when dealing with this life altering autoimmune disease. The video features actor, Jason Alexander; Football Hall of Famer, Barry Sanders; Actor and Comedian, Mark Teich; Author and Personality,…
In a new research paper, scientists at the Faculty of Dentistry, Aristotle University of Thessaloniki, Greece, presented a clinical report of a systemic sclerosis case where the jaw was affected. The research paper, whose goal is to raise awareness among oral radiologists and other health professionals, is entitled “…
In a new study entitled “Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation,” a team of researchers investigated whether patients with systemic sclerosis present changes in their immune B cells profile (including frequency and activation phenotypes), focusing particularly on the B…
iBio, Inc., a plant-based biotechnology company focused on developing biological therapies for several fibrotic diseases including idiopathic pulmonary fibrosis and systemic sclerosis, recently announced it has received a notification from the European Patent Office stating that the opposition period for the iBio patent 2192172, entitled “System for Expression of…
Reata Pharmaceuticals, Inc., a biopharmaceutical company based in Irving, Texas, recently announced positive data from the Phase 2 clinical trial LARIAT assessing the company’s candidate product bardoxolone methyl for pulmonary arterial hypertension (PAH). The results were recently presented by Dr. Ronald Oudiz, Director of the Pulmonary Hypertension Center and…
Recent Posts
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show